Harura et al. suggested that high pStat3 expression was related to smaller tumor size, limited smoking, and an anti-apoptosis effect on early NSCLC, and that agents targeting the EGFR-Stat3 pathway may have better efficiency in early-stage NSCLC patients compared to advanced-stage patients [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.